Method of regulating glucose metabolism, and reagents related thereto
View Patent ↗One aspect of the present invention relates to a method for treating Type II diabetes in an animal, comprising conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV or a pharmaceutically acceptable salt thereof in an amount sufficient to treat Type II diabetes of the animal but not sufficient to suppress the animal's immune system.
1. A method for treating type II diabetes in an animal, comprising conjointly administering to the animal (i) metformin, and (ii) an inhibitor of dipeptidylpeptidase IV represented in the general formula:
or a pharmaceutically acceptable salt thereof, wherein
R 1 represents a C-terminally linked amino acid residue or amino acid analog, or a C-terminally linked peptide or peptide analog, or
R 6 represents hydrogen, a halogen, an alkyl, an alkenyl, an alkynyl, an aryl, —(CH 2 ) m —R 7 , —(CH 2 ) m —OH, —(CH 2 ) m -O-alkyl, —(CH 2 ) m —O-alkenyl, —(CH 2 ) m —O-alkynyl, —(CH 2 ) m —O—(CH 2 ) m —R 7 , —(CH 2 ) m —SH, —(CH 2 ) m —S-alkyl, —(CH 2 ) m —S-alkenyl, —(CH 2 ) m —S-alkynyl, —(CH 2 ) m —S—(CH 2 ) m —R 7 ,
R 7 represents an aryl, a cycloalkyl, a cycloalkenyl, or a heterocycle;
R 8 and R 9 each independently represent hydrogen, alkyl, alkenyl, —(CH 2 ) m —R 7 , —C(═O)-alkyl, —C(═O)-alkenyl, —C(═O)-alkynyl, —C(═O)—(CH 2 ), —R 7 , or R 8 and R 9 taken together with the N atom to which they are attached complete a heterocyclic ring having from 4 to 8 atoms in the ring structure; R 11 and R 12 each independently represent hydrogen, an alkyl, or a pharmaceutically acceptable salt, or R 11 and R 12 taken together with the O—B—O atoms to which they are attached complete a heterocyclic ring having from 5 to 8 atoms in the ring structure;
m is zero or an integer in the range of 1 to 8; and
n is an integer in the range of 1 to 8, and
wherein the inhibitor inhibits dipeptidylpeptidase proteolysis of GLP-1 with a Ki of less than about 10 nM, wherein the metformin and inhibitor are administered in an amount sufficient to treat Type II diabetes but not sufficient to suppress the immune system of the animal.
2. The method of claim 1 , wherein said conjointly administering is achieved by separate dosing of the metformin and inhibitor.
3. The method of claim 1 , wherein said conjointly administering is achieved by administering the metformin and inhibitor in the same composition.
4. The method of claim 2 or 3 , wherein the inhibitor has a Ki for inhibition of dipeptidylpeptidase proteolysis of GLP-1 of 1.0 nm or less.
5. The method of claim 1 , 2 or 3 , wherein the inhibitor has a molecular weight less than 7500 amu.
6. The method of claim 1 , 2 or 3 , wherein the metformin and the inhibitor are administered orally.